ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that an interaction with individual shareholder/investor is scheduled to be held as per the details attached
AstraZeneca in touch with Indian authorities for approval to Covid drug
The company said it has initiated engagements with Indian health authorities regarding its Covid prevention drug for people with weakened immune system
Ipca, AstraZeneca, Torrent, Sun Pharma outshine Indian pharma market in Nov
Growth in volume terms, however, remained flat year-on-year during November, but it was the 5.4% rise in prices and new product launches that helped drive IPM growth ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated December 2, 2021 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the below request for loss of share certificate from the claimant
Next pandemic could be more lethal than Covid: AstraZeneca vaccine maker
Future pandemics could be even more lethal than Covid so the lessons learned from the pandemic must not be squandered, one of the creators of the Oxford-AstraZeneca vaccine said.
AstraZeneca studies listing of new vaccines division
AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.
Booster dose of six COVID vaccines safe, increases immunity: Lancet study
The vaccines studied were AstraZeneca, Pfizer-BioNTech, Novavax, Janssen, Moderna, Valneva, and Curevac. AstraZeneca Pharma India Ltd - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated November 3, 2021 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. AstraZeneca Pharma India Ltd - 506820 - Disclosure Of Related Party Transactions
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended September 30, 2021 for your information and records.